Nevertheless, not differently than in many other GRPR-targeting projects, the typical accumulation region during this study turned out to be the pancreas (39.83 ± 2.76% injected activity at 1 h) as there are approximately seven times more GRPR sites to bind than in prostate tumor. Here, GRPR is linked to prostate neoplasm.